Pharma major Wockhardt continued its downtrend today as the company decided to recall its remaining batches of drugs from the US market, which was manufactured prior to the USFDA import alerts. On Monday, the share plunged 18.31 percent to close at Rs 1,330.05 on the BSE. The company in its filing said as a measure of preparedness and as an abundant precaution, the company has now decided to recall, as a part of remedial measure all the remaining batches in the US market that were manufactured prior to the US FDA import alerts even though there is no evidence of risk to patient safety from the products currently available in the US market. During the last USFDA cGMP inspection of the facilities at L1- Chikalthana and Waluj in Aurangabad, Maharashtra, some observations were reported pertaining to batches of some products manufactured prior to the USFDA import alerts.
Whereas the company continued to supply some of the products in the US market manufactured in the same facilities, several batches of other products, manufactured prior to the import alerts may still be in the US market.
For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com/
✆ - 0731-6554125 | Toll Free - 1800-3010-2007
0 comments:
Post a Comment